Cite
HARVARD Citation
Carlino, M. et al. (2018). Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. European journal of cancer. pp. 236-243. [Online].